Episode Details

Back to Episodes
ASGCT 2025: The co-founders of Circio describe the properties they believe make circular RNA a better, more durable medium for use in gene and cell therapies

ASGCT 2025: The co-founders of Circio describe the properties they believe make circular RNA a better, more durable medium for use in gene and cell therapies

Published 1 year, 4 months ago
Description

CEO Erik Wiklund and CTO Thomas Hansen describe what circular RNA is, and explain their groundbreaking work where they discovered circular RNA in humans over a decade ago. They discuss potential use cases, including using it for in-vivo CAR-T, something that has been talked about a lot at this year's conference.

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us